STOCK TITAN

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET to present results and a corporate update.

Participants may access the live webcast online; a recorded version will be posted on the company website shortly after the call and archived for approximately 90 days.

Tarsus (NASDAQ: TARS) riporterà i risultati finanziari del terzo trimestre 2025 il martedì 4 novembre 2025. L'azienda organizzerà una trasmissione web in diretta alle 1:30 p.m. PT / 4:30 p.m. ET per presentare i risultati e un aggiornamento aziendale.

I partecipanti potranno accedere alla trasmissione in diretta online; una versione registrata sarà pubblicata sul sito web dell'azienda poco dopo la chiamata e archiviata per circa 90 giorni.

Tarsus (NASDAQ: TARS) reportará los resultados financieros del tercer trimestre de 2025 el martes 4 de noviembre de 2025. La empresa organizará una transmisión web en vivo a las 1:30 p.m. PT / 4:30 p.m. ET para presentar resultados y una actualización corporativa.

Los participantes podrán acceder a la transmisión en vivo en línea; una versión grabada se publicará en el sitio web de la empresa poco después de la llamada y se archivará por aproximadamente 90 días.

타르서스(TARS: NASDAQ)2025년 3분기 실적을 2025년 11월 4일 화요일에 발표합니다. 회사는 라이브 웹캐스트PT 오후 1:30 / ET 오후 4:30에 개최하여 실적 발표 및 기업 업데이트를 제공합니다.

참석자들은 온라인으로 라이브 웹캐스트에 접속할 수 있으며, 콜 직후에 녹화본이 회사 웹사이트에 게시되고 약 90일 동안 보관됩니다.

Tarsus (NASDAQ: TARS) publiera les résultats financiers du troisième trimestre 2025 le mardi 4 novembre 2025. L'entreprise organisera une diffusion en direct à 13 h 30 PT / 16 h 30 HE pour présenter les résultats et une mise à jour de l'entreprise.

Les participants pourront accéder à la diffusion en direct en ligne; une version enregistrée sera publiée sur le site Web de l'entreprise peu après l'appel et sera archivée pendant environ 90 jours.

Tarsus (NASDAQ: TARS) wird die Finanzergebnisse des dritten Quartals 2025 am Dienstag, dem 4. November 2025 bekannt geben. Das Unternehmen wird eine Live-Webcast um 13:30 PT / 16:30 ET hosten, um Ergebnisse und ein Unternehmensupdate vorzustellen.

Teilnehmer können über das Internet auf die Live-Webcast zugreifen; eine aufgezeichnete Version wird kurz nach dem Call auf der Unternehmenswebsite veröffentlicht und für ca. 90 Tage archiviert.

تارسس (ناسداك: TARS) ستعلن عن نتائجها المالية للربع الثالث من 2025 في الثلاثاء 4 نوفمبر 2025. ستستضيف الشركة بثاً مباشراً في الساعة 1:30 مساءً بتوقيت المحيط الهادئ / 4:30 مساءً بتوقيت شرق الولايات المتحدة لتقديم النتائج وتحديثاً للشركة.

يمكن للمشاركين الوصول إلى البث المباشر عبر الإنترنت؛ سيتم نشر نسخة مسجلة على موقع الشركة قريباً بعد الاتصال وأرشفتها لما يقارب 90 يوماً.

Tarsus (NASDAQ: TARS) 将在2025年第三季度的财报于2025年11月4日,星期二公布。公司将举行在线直播网络广播,时间为太平洋时间13:30 / 东部时间16:30,以发布业绩及公司更新。

参与者可以在线访问直播网络广播;会后不久将在公司网站上发布录音版本,并将大约保存90天

Positive
  • None.
Negative
  • None.

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
 
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com



FAQ

When will Tarsus (TARS) report Q3 2025 results?

Tarsus will report Q3 2025 results on Tuesday, November 4, 2025.

What time is the Tarsus (TARS) Q3 2025 webcast?

The live webcast is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.

How can investors access the Tarsus (TARS) November 4 webcast?

Investors may access the live webcast via the company's website using the provided webcast link.

Will there be a replay of the Tarsus (TARS) Q3 2025 earnings call?

Yes. A recorded version will be posted shortly after the webcast and archived on the website for about 90 days.

What will Tarsus (TARS) cover during the November 4, 2025 call?

Tarsus will report its third quarter 2025 financial results and provide a corporate update.

Is there a dial-in number or only a webcast for the Tarsus (TARS) Q3 2025 report?

The announcement specifies a live webcast and archived recording; no dial-in details are provided in the notice.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

2.88B
39.24M
3.18%
118.17%
16.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE